PharmaFEATURES的动态

CircRNAs provide a promising avenue for non-invasive testing and molecular characterization, while IHC remains a cornerstone of traditional cancer pathology. The article "Circular RNAs in Breast Cancer: Diagnosis, Treatment, and Prognosis," demonstrated how circRNAs can help in the early detection of breast cancer due to their stability in body fluids and specific expression patterns in cancerous tissues. Monitoring circRNA levels could help predict disease progression and patient survival. Read the full article here: https://buff.ly/4f9U1Ud

Tumor–immune interactions in the core and periphery of solid tumors are critical factors influencing tumor progression and response to therapy. See how #spatialtranscriptomics tools revealed these cellular interactions and other therapeutically relevant insights in a summary of our recent bioRxiv preprint, featuring #VisiumHD and #XeniumInSitu data from human FFPE colorectal cancer tissue: https://bit.ly/3ZcStCU

Widespread clinical use of MRI radiomic tumor profiling for prognostication and treatment planning in cancers faces major obstacles due to limitations in standardization of radiomic features. In this work, we assess the impact of different MRI scanning- and normalization protocols for the statistical analyses of tumor radiomic data in two patient cohorts with uterine endometrial- and cervical cancer. https://lnkd.in/dcSdxvYW

?? Recent clinical trial results demonstrated the potential of an investigational visualization system to identify residual #breastcancer following removal of the primary specimen during initial lumpectomy. In the study, the Lumicell Direct Visualization System (DVS) identified cancer remaining after the standard-of-care lumpectomy procedure in approximately 8% of patients. In the majority of these patients, standard pathology assessment had deemed margins negative and would have left the tumor behind. In this interview, Barbara Smith, MD, PhD, discusses the Lumicell Direct Visualization System and how it can enhance breast cancer detection. ???? Watch Now?:

Did You Know: In addition to PSA Tests and DREs, there are two other early-detection tests for more advanced prostate cancers. Trans-Perineal Biopsies and Trans-Rectal Ultrasound (TRUS) Guided Biopsies are two imaging tests used for detecting prostate cancer when PSA Tests and DREs are deemed inconclusive. To learn more about prostate cancer biopsy and imaging, click here: https://lnkd.in/gHNUJAgK #ProstateCancerAwareness #ProstateCancer #EarlyDetectionSavesLives

I #TRONpublications I A hallmark of pancreatic #cancer (PDAC) is neural infiltration by tumor cells. A multidiscipliary research team from the Technische Universit?t München (Technical University of Munich) coordinated by Ekin Demir and Güralp Ceyhan with support of the Clinical Pathology Unit at TRON evaluated a large cohort of #PDAC patients for neural invasion in a standardized manner in tissue of resection specimen. Here, the team could establish neural invasion as a strong predictor for local tumor recurrence. Our pathologist Matthias Gaida was involved in tissue analysis in this clincial relevant project, which is a first step into a novel collaborative work with the group of Ekin Demir to deeper investigate the complex crosstalk of immune cell axis to nerves and cancer cells in PDAC. Read the full article here ????https://lnkd.in/evqs3NXh #TRONMainz #collaboration

Breast Cancer Can Now Be Detected 4 to 6 years Before it Developed, Thanks to AI. The Full Study Below. In this retrospective population-based cohort study involving multiple rounds of routine mammography in a national screening program, we found that a cancer detection AI algorithm was able to estimate future breast cancer based on a mammography performed 4 to 6 years before diagnosis. https://lnkd.in/giT7ETZC More Details in This Study.

Artificial Intelligence is improving the accuracy and speed of breast cancer diagnosis by analyzing mammograms and biopsy results. A recent study shows how AI can help detect cancers that might be missed by the human eye, leading to earlier and more effective treatments. Read the research here: #BreastCancer #AIInHealthcare #EarlyDetection #MedicalInnovation

As breast cancer treatments evolve toward personalized care, molecular imaging has become essential to optimize drug development and clinical decision-making. New imaging techniques, such as FES-PET, which uses a fluoroestradiol F-18 to visualize and measure the concentration of estrogen receptors in the body, may help overcome challenges in traditional approaches. Join Gisela Menezes Montgomery, MD, PhD as she discusses FES-PET and other recent advances in molecular breast cancer imaging. https://hubs.ly/Q02Hvgbm0 #breastcancer #CRO

Happy to share our latest paper on #FLASH_RT, just out in MCT. In partnership with #IBA ( Swati Girdhani, Fran?ois Vander Stappen, Nicolas Denef), work by postdoc Priyanka Chowdhury, Ph.D. and colleagues at #PennRadOnc, demonstrates that Proton FLASH reduces substantially normal tissue toxicity and improves overall survival in mouse preclinical models of Head & Neck cancer. https://lnkd.in/erbHYXe5